Table: begin end state 1 30 cytoplasmic 31 56 transmembrane 57 67 non-cytoplasmic 68 85 transmembrane 86 96 cytoplasmic 97 116 transmembrane 117 121 non-cytoplasmic 122 143 transmembrane 144 161 cytoplasmic 162 181 transmembrane 182 186 non-cytoplasmic 187 209 transmembrane 210 270 cytoplasmic 271 293 transmembrane 294 308 non-cytoplasmic 309 330 transmembrane 331 338 cytoplasmic 339 360 transmembrane 361 366 non-cytoplasmic 367 393 transmembrane 394 404 cytoplasmic 405 426 transmembrane 427 429 non-cytoplasmic 430 431 transmembrane 432 435 non-cytoplasmic 436 455 transmembrane 456 472 cytoplasmic
Input: >Pf6N2E2_883 Major myo-inositol transporter IolT MTINSYGNTADTSAAYVSPEKHQAQRYLQKITWIATFGGLLFGFDTGVINGALLYMKDDL GLTPFTEGLVASALLIGAMMGALFSGRLSDLKGRRRIILFLAVVFFLGALACALAPTLDV MVAARFTLGLAVGGASVVVPAYLSEMAPSSIRGRIITRNELMIVTGQFLAFTTNATLGNL FSDLDGVWRWMLALATLPAVALWLGMLYMPESPRWLATKGRFREGLEVLKLVREEYYAKA EMEAITQQISNERFIKKGGWRDLSQKGARRIFLIGIGIAVTSQLTGVNSIMYFGTQILTE AGLEQRSALIANVVNGIISIGATFVGIALLDRVGRRPMMLLGFTGTTLSLLLIGLVSVFV DPSVTRAMLILGAMAMFLASMQGLIGPAFWVLLAEIFPMRIRGGCMGMAIAAFWLTNVMI GMFFPSLVAMIGIGQTFFVFVGAGLLSLTFVAVWVPETRGSTLEEIEQRLYG
Or try the official Phobius web server, which has a different display
Reference: Advantages of combined transmembrane topology and signal peptide prediction - the Phobius web server